Accuracy of the online prognostication tools PREDICT and Adjuvant! for early-stage breast cancer patients younger than 50 years
Ellen G. Engelhardt(The Netherlands Cancer Institute), Marjanka K. Schmidt(University of Cambridge), Laura van ‘t Veer, Emiel J. Rutgers(Oncode Institute), Flora E. van Leeuwen(The Netherlands Cancer Institute), Rob A.�E.�M. Tollenaar(Leiden University Medical Center), Alexandra J. van den Broek(The Netherlands Cancer Institute), Pieter J. Westenend(Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital), Anne M. Stiggelbout(University Medical Center Groningen), Sabine C. Linn(Oncode Institute), Sabine Siesling(Netherlands Comprehensive Cancer Organisation), Peter M. Ravdin(The University of Texas MD Anderson Cancer Center), Vincent T.H.B.M. Smit(Leiden University Medical Center), Caroline Seynaeve(Radboud University Nijmegen), Paul D Pharaoh(University of Cambridge), Anthonie O. van de Velde(The Netherlands Cancer Institute), Adri C. Voogd(Maastricht University Medical Centre), Gordon Wishart(Anglia Ruskin University), Mariël Brinkhuis(Leiden University Medical Center)
Cited by 60
Related Papers
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
|New England Journal of Medicine|2002|6.5k
Current and future burden of breast cancer: Global statistics for 2020 and 2040
|The Breast|2022|3.3k
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k